scholarly journals 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

2021 ◽  
Vol 32 ◽  
pp. S691-S692
Author(s):  
D.F. McDermott ◽  
J-L. Lee ◽  
G.A. Bjarnason ◽  
J. Larkin ◽  
R. Gafanov ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
First Line ◽  
Cell Renal Cell Carcinoma ◽  
First Line Therapy ◽  
Line Therapy

Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 4500-4500 ◽  
Author(s):  
David F. McDermott ◽  
Jae-Lyun Lee ◽  
Cezary Szczylik ◽  
Frede Donskov ◽  
Jahangeer Malik ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
First Line ◽  
Cell Renal Cell Carcinoma ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy

2017 ◽  
Vol 12 (4) ◽  
pp. 487-494 ◽  
Author(s):  
Solène-Florence Kammerer-Jacquet ◽  
Sarah Medane ◽  
Karim Bensalah ◽  
Jean-Christophe Bernhard ◽  
Mokrane Yacoub ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
First Line ◽  
Cell Renal Cell Carcinoma ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)

2018 ◽  
Vol 29 ◽  
pp. viii307 ◽  
Author(s):  
F. Donskov ◽  
D.F. McDermott ◽  
J.L. Lee ◽  
C. Szczylik ◽  
J. Malik ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
First Line ◽  
Cell Renal Cell Carcinoma ◽  
First Line Therapy ◽  
Line Therapy

Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 520-520
Author(s):  
Ilya Tsimafeyeu ◽  
Natalia N. Petenko ◽  
Anton Snegovoy ◽  
Sergey Varlamov ◽  
Lev V. Demidov
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Performance Status ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Ecog Ps

520 Background: Targeted therapy has improved clinical outcomes in metastatic renal cell carcinoma (mRCC). However, patients with unfavorable performance status are often under-represented in clinical trials of mRCC. Methods: Patients with mRCC (clear or non-clear cell) and ECOG PS >2 were included in retrospective study.Primary objective of this study was to evaluate the overall duration of targeted therapy (ODT). ODT was defined as time from initiation of first-line therapy until the end of last-line therapy. Results: 79 patients with ECOG PS >2 (median age, 60 [48-70]; male, 73%; clear-cell RCC, 95%; MSKCC intermediate/poor risk, 97%/3%) were treated with sunitinib (77%), sorafenib (23%), everolimus (20%), bevacizumab + IFN (15%), pazopanib (4%), temsirolimus (2.5%) of which 55 (70%) received only first-line therapy, 24 (30%) received 2 lines, and 9 (11%) received 3 lines of therapy. The median ODT was 9.8 months (95% CI 6–13.6). The median time to progression of patients that received 1, 2 or 3 lines was 7.1, 5.9, and 6.3 months, respectively. One patient showed complete response and 2 patients had partial responses during first-line therapy, 2 patients had partial responses during second-line therapy, and 1 patient had partial response after 2 months of third-line therapy. Among the patients who discontinued treatment, disease progression was the most common reason for discontinuation. There was no unexpected serious toxicity. Conclusions: mRCC patients with unfavorable performance status could be treated with targeted therapy during 9.8 months.

Sign in / Sign up

Export Citation Format

Share Document